Company: DRTSW
Filing Date: 2025-06-23
Form Type: F-3
Source: 0001213900-25-056744
Chunk: 7

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-06-23
Form: F-3
Chunk 7
---
; Incorporation of Information by Reference” elsewhere in this prospectus.

Market,
ranking and industry data used throughout this prospectus, including statements regarding market size and technology adoption rates,
is based on the good faith estimates of our management, which in turn are based upon our management’s review of internal surveys,
independent industry surveys and publications including third party research and publicly available information. These data involve a
number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While we are not aware of any
misstatements regarding the industry data presented herein, our estimates involve risks and uncertainties and are subject to change based
on various factors, including those discussed under the heading “Risk Factors” in this prospectus and under the headings
“Risk Factors” and “Operating and Financial Review and Prospects” in our Annual Report on
Form 20-F for the year ended December 31, 2024 (our “Annual Report”), incorporated by reference into this prospectus.

<div align='center'>iii

SUMMARY OF THE PROSPECTUS</div>

This summary highlights, and is qualified in its entirety by, the more detailed information included elsewhere in this prospectus. This summary does not contain all of the information that may be important to you. You should read and carefully consider the entire prospectus, especially the “Risk Factors” section of this prospectus and in our Annual Report, before deciding to invest in our ordinary shares. Unless the context otherwise requires, we use the terms “company,” “we,” “us” and “our” in this prospectus to refer to Alpha Tau Medical Ltd. and subsidiaries.

We
are a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range
of alpha particles for use as a localized radiation therapy for solid tumors. Our proprietary Alpha DaRT technology is
designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit,
the traditional shortcomings of alpha radiation’s limited range. We believe that our Alpha DaRT technology has the potential to
be broadly applicable across multiple targets and tumor types. We are currently focused on developing the Alpha DaRT for use in a number
of potential applications, particularly in refractory or unresectable localized tumors which are not being adequately addressed by standard
of care, tumor types with a high unmet need (such as pancreatic adenocarcinoma or glioblastoma multiforme), and metastatic tumors in combination
with